Metabolic Effects Significantly Lower With INVEGA(R) Compared To Olanzapine
New data from a 6-month open label randomised controlled trial show INVEGA® (paliperidone ER) is associated with significantly less metabolic effects compared to oral olanzapine in people with schizophrenia, while demonstrating comparable efficacy.1 The results were presented at the 15th Biennial Winter Workshop in Psychoses in Barcelona, Spain. (Source: Health News from Medical News Today)div id=medwormpbiMedWorm Message:/i/b Please have a look at this new site driven by MedWorm: a href=http://www.thebreastcancerdaily.com/ target=_blankThe Breast Cancer Daily/a/p/div

Table of Contents
New Medication Paliperidone (Invega) Approved for Treatment of SchizophreniaCitalopram Shows Limited Effect on Compulsive Sexual BehaviorDelirium Associated with Bupropion and FluoxetineQuetiapine and Quality of Life in Bipolar DepressionIM Aripiprazole for Agitation in SchizophreniaStudy Examines Psychotropic Drug Use in Children with MRComparing HAM-D-6 with HAM-D-17Hyperglycemia in a Child Treated with AripiprazoleApproval: Paliperidone for SchizophreniaApproval: First Generic Wellbutrin XR (Source: The Brown University Psychopharmacology Update)